Cytomegalovirus and other herpesviruses after hematopoietic
cell and solid organ transplantation: From antiviral drugs to
virus-specific T cells

J 2022

Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells

ŤAPUCHOVÁ, Ivana, Robert PYTLIK, Pavel ŠIMARA, Lenka TESAŘOVÁ, Irena KOUTNÁ et. al.

Basic information

Original name

Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells

Authors

ŤAPUCHOVÁ, Ivana (703 Slovakia, belonging to the institution), Robert PYTLIK (203 Czech Republic), Pavel ŠIMARA (203 Czech Republic, belonging to the institution), Lenka TESAŘOVÁ (203 Czech Republic, belonging to the institution) and Irena KOUTNÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Transplant Immunology, Amsterdam, Elsevier B.V. 2022, 0966-3274

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30102 Immunology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.500

RIV identification code

RIV/00216224:14110/22:00125593

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.trim.2022.101539

UT WoS

000746028600010

Keywords in English

Virus-specific T cells; Herpesviruses; Adoptive transfer; Cytomegalovirus; Resistance; Interferon gamma; Immunotherapy

Abstract

V originále

Herpesviruses can either cause primary infection or may get reactivated after both hematopoietic cell and solid organ transplantations. In general, viral infections increase post-transplant morbidity and mortality. Prophylactic, preemptive, or therapeutically administered antiviral drugs may be associated with serious side effects and may induce viral resistance. Virus-specific T cells represent a valuable addition to antiviral treatment, with high rates of response and minimal side effects. Even low numbers of virus-specific T cells manufactured by direct selection methods can reconstitute virus-specific immunity after transplantation and control viral replication. Virus-specific T cells belong to the advanced therapy medicinal products, and their production is regulated by appropriate legislation; also, strict safety regulations are required to minimize their side effects.

Links

LM2018133, research and development project

Name: Český národní uzel Evropské infrastruktury pro translační medicínu (Acronym: EATRIS-ERIC-CZ)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

ŤAPUCHOVÁ, Ivana, Robert PYTLIK, Pavel ŠIMARA, Lenka TESAŘOVÁ and Irena KOUTNÁ. Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells. Transplant Immunology. Amsterdam: Elsevier B.V., 2022, vol. 71, April, p. 1-13. ISSN 0966-3274. Available from: https://dx.doi.org/10.1016/j.trim.2022.101539.

@article{1843917,
   author = {Ťapuchová, Ivana and Pytlik, Robert and Šimara, Pavel and Tesařová, Lenka and Koutná, Irena},
   article_location = {Amsterdam},
   article_number = {April},
   doi = {http://dx.doi.org/10.1016/j.trim.2022.101539},
   keywords = {Virus-specific T cells; Herpesviruses; Adoptive transfer; Cytomegalovirus; Resistance; Interferon gamma; Immunotherapy},
   language = {eng},
   issn = {0966-3274},
   journal = {Transplant Immunology},
   title = {Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells},
   url = {https://www.sciencedirect.com/science/article/pii/S0966327422000132},
   volume = {71},
   year = {2022}
}

TY  - JOUR
ID  - 1843917
AU  - Ťapuchová, Ivana - Pytlik, Robert - Šimara, Pavel - Tesařová, Lenka - Koutná, Irena
PY  - 2022
TI  - Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells
JF  - Transplant Immunology
VL  - 71
IS  - April
SP  - 1-13
EP  - 1-13
PB  - Elsevier B.V.
SN  - 09663274
KW  - Virus-specific T cells
KW  - Herpesviruses
KW  - Adoptive transfer
KW  - Cytomegalovirus
KW  - Resistance
KW  - Interferon gamma
KW  - Immunotherapy
UR  - https://www.sciencedirect.com/science/article/pii/S0966327422000132
N2  - Herpesviruses can either cause primary infection or may get reactivated after both hematopoietic cell and solid organ transplantations. In general, viral infections increase post-transplant morbidity and mortality. Prophylactic, preemptive, or therapeutically administered antiviral drugs may be associated with serious side effects and may induce viral resistance. Virus-specific T cells represent a valuable addition to antiviral treatment, with high rates of response and minimal side effects. Even low numbers of virus-specific T cells manufactured by direct selection methods can reconstitute virus-specific immunity after transplantation and control viral replication. Virus-specific T cells belong to the advanced therapy medicinal products, and their production is regulated by appropriate legislation; also, strict safety regulations are required to minimize their side effects.
ER  -

ŤAPUCHOVÁ, Ivana, Robert PYTLIK, Pavel ŠIMARA, Lenka TESAŘOVÁ and Irena KOUTNÁ. Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells. \textit{Transplant Immunology}. Amsterdam: Elsevier B.V., 2022, vol.~71, April, p.~1-13. ISSN~0966-3274. Available from: https://dx.doi.org/10.1016/j.trim.2022.101539.

Detailed Information on Publication Record